The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of nivolumab and ipilimumab combined with nintedanib in advanced NSCLC.
 
Sonam Puri
No Relationships to Disclose
 
Sandrine Niyongere
No Relationships to Disclose
 
Monica Sheila Chatwal
No Relationships to Disclose
 
Theresa A. Boyle
Other Relationship - Bristol-Myers Squibb
 
Dung-Tsa Chen
Research Funding - Abbvie (Inst)
 
David Noyes
No Relationships to Disclose
 
Scott Joseph Antonia
Stock and Other Ownership Interests - Cellular Biomedicine Group
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Novartis
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck
 
Jhanelle Elaine Gray
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Genentech/Roche; Janssen; Lilly
Speakers' Bureau - Genentech
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Epic Sciences (Inst); Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Genentech/Roche; Janssen Oncology